Cargando…
Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia encountered in clinical practice affecting up to 10% of the population over 60 years old and its prevalence rises with age. The main goals were to characterize the AF patient population after the initial diagnosis of AF...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358274/ https://www.ncbi.nlm.nih.gov/pubmed/28392870 http://dx.doi.org/10.14740/cr324e |
_version_ | 1782516204412338176 |
---|---|
author | Clua-Espuny, Jose Luis Panisello-Tafalla, Anna Lopez-Pablo, Carlos Lechuga-Duran, Inigo Bosch-Princep, Ramon Lucas-Noll, Jorgina Gonzalez-Henares, Antonia Queralt-Tomas, Lluisa Ripolles-Vicente, Rosa Calduch-Noll, Cristina Gonzalez-Rojas, Nuria Gallofre-Lopez, Miguel |
author_facet | Clua-Espuny, Jose Luis Panisello-Tafalla, Anna Lopez-Pablo, Carlos Lechuga-Duran, Inigo Bosch-Princep, Ramon Lucas-Noll, Jorgina Gonzalez-Henares, Antonia Queralt-Tomas, Lluisa Ripolles-Vicente, Rosa Calduch-Noll, Cristina Gonzalez-Rojas, Nuria Gallofre-Lopez, Miguel |
author_sort | Clua-Espuny, Jose Luis |
collection | PubMed |
description | BACKGROUND: Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia encountered in clinical practice affecting up to 10% of the population over 60 years old and its prevalence rises with age. The main goals were to characterize the AF patient population after the initial diagnosis of AF and to determine overall survival. METHODS: It is a real-life observational study of 269 subjects with an AF diagnosis over 60 years old randomly selected. The collected variables were: sociodemographic, cardiovascular complications/comorbidities (CVCs) included in the CHA(2)DS(2)-VASc and HAS_BLED scores, drug assigned as clinical treatment, mean range INR and CVCs and death dates (all-cause mortality). The survival curve and the risk of death were assessed using Kaplan-Meier survival curve and comparisons with log-rank. RESULTS: The average following time was 6.2 ± 3.7 years (0.2-20.4). Eleven point five percent died. Sixty-five point four percent had some CVCs. There were no differences in the overall incidence of CVCs by gender. The survival probability was 0.86 ± DE 0.03 among men and 0.90 ± DE 0.04 among women without differences. Thirty-six point eight percent (95% CI: 30.8 - 42.7) were diagnosed vascular complications before AF diagnosis, being ischemic cardiopathy (24.2%) and ischemic stroke (23.2%) the most frequent. The mortality is higher (P < 0.036) among those who suffered ≥ 3 vascular complications and significantly lower among those treated with statins (P = 0.032). After AF diagnosis, the most frequent was the cardiac heart failure (46.7%), significantly higher among women (P = 0.037). The mortality is significantly lower in those treated with OAC (P = 0.003). CONCLUSIONS: AF is associated with ischemic heart disease, ischemic stroke and congestive heart failure, but the average mortality age is not different from the global population in Spain and Catalonia. |
format | Online Article Text |
id | pubmed-5358274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53582742017-04-07 Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study Clua-Espuny, Jose Luis Panisello-Tafalla, Anna Lopez-Pablo, Carlos Lechuga-Duran, Inigo Bosch-Princep, Ramon Lucas-Noll, Jorgina Gonzalez-Henares, Antonia Queralt-Tomas, Lluisa Ripolles-Vicente, Rosa Calduch-Noll, Cristina Gonzalez-Rojas, Nuria Gallofre-Lopez, Miguel Cardiol Res Original Article BACKGROUND: Atrial fibrillation (AF) is the most common cardiac tachyarrhythmia encountered in clinical practice affecting up to 10% of the population over 60 years old and its prevalence rises with age. The main goals were to characterize the AF patient population after the initial diagnosis of AF and to determine overall survival. METHODS: It is a real-life observational study of 269 subjects with an AF diagnosis over 60 years old randomly selected. The collected variables were: sociodemographic, cardiovascular complications/comorbidities (CVCs) included in the CHA(2)DS(2)-VASc and HAS_BLED scores, drug assigned as clinical treatment, mean range INR and CVCs and death dates (all-cause mortality). The survival curve and the risk of death were assessed using Kaplan-Meier survival curve and comparisons with log-rank. RESULTS: The average following time was 6.2 ± 3.7 years (0.2-20.4). Eleven point five percent died. Sixty-five point four percent had some CVCs. There were no differences in the overall incidence of CVCs by gender. The survival probability was 0.86 ± DE 0.03 among men and 0.90 ± DE 0.04 among women without differences. Thirty-six point eight percent (95% CI: 30.8 - 42.7) were diagnosed vascular complications before AF diagnosis, being ischemic cardiopathy (24.2%) and ischemic stroke (23.2%) the most frequent. The mortality is higher (P < 0.036) among those who suffered ≥ 3 vascular complications and significantly lower among those treated with statins (P = 0.032). After AF diagnosis, the most frequent was the cardiac heart failure (46.7%), significantly higher among women (P = 0.037). The mortality is significantly lower in those treated with OAC (P = 0.003). CONCLUSIONS: AF is associated with ischemic heart disease, ischemic stroke and congestive heart failure, but the average mortality age is not different from the global population in Spain and Catalonia. Elmer Press 2014-02 2014-02-27 /pmc/articles/PMC5358274/ /pubmed/28392870 http://dx.doi.org/10.14740/cr324e Text en Copyright 2014, Clua-Espuny et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Clua-Espuny, Jose Luis Panisello-Tafalla, Anna Lopez-Pablo, Carlos Lechuga-Duran, Inigo Bosch-Princep, Ramon Lucas-Noll, Jorgina Gonzalez-Henares, Antonia Queralt-Tomas, Lluisa Ripolles-Vicente, Rosa Calduch-Noll, Cristina Gonzalez-Rojas, Nuria Gallofre-Lopez, Miguel Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title_full | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title_fullStr | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title_full_unstemmed | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title_short | Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study |
title_sort | atrial fibrillation and cardiovascular comorbidities, survival and mortality: a real-life observational study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358274/ https://www.ncbi.nlm.nih.gov/pubmed/28392870 http://dx.doi.org/10.14740/cr324e |
work_keys_str_mv | AT cluaespunyjoseluis atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT panisellotafallaanna atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT lopezpablocarlos atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT lechugaduraninigo atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT boschprincepramon atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT lucasnolljorgina atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT gonzalezhenaresantonia atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT queralttomaslluisa atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT ripollesvicenterosa atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT calduchnollcristina atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT gonzalezrojasnuria atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy AT gallofrelopezmiguel atrialfibrillationandcardiovascularcomorbiditiessurvivalandmortalityareallifeobservationalstudy |